Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study
Authors:
Open Access
- 10 March 2012
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (7) , 1113-1120
Abstract
Background and purpose: Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Materials and methods: Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m2 per day and increased by steps of 3 mg/m2 per day. Results: At a daily dose of 16 mg/m2, one out of six patients developed a grade 4 leukopenia, and one a grad 3 pneumonitis. Further grade III toxicity was not observed. The dose of 13 mg/m2 was identified as the MTD. All patients developed a fludarabine dose-dependent lymphocytopenia. Conclusion: Fludarabine can be safely administered concurrently with radiation at a daily dose of 13 mg/m2 during the final 2 weeks of radiotherapy. Further prospective clinical studies are required to establish the potential role of concurrent fludarabine and radiotherapy in the treatment of locally advanced inoperable NSCLC.Keywords
This publication has 49 references indexed in Scilit:
- Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II studyLung Cancer, 2008
- Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell linesin vitroInternational Journal of Radiation Biology, 2008
- Therapeutic options for regionally advanced non-small cell lung cancerLung Cancer, 1996
- Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non–small cell lung cancerCancer, 1993
- Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung CancerNew England Journal of Medicine, 1992
- Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 PatientsJNCI: Journal of the National Cancer Institute, 1991
- Cytotoxic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning systemEuropean Journal of Cancer and Clinical Oncology, 1988
- The potentiation of radiation response on murine tumor by fludarabine phosphateCancer Letters, 1986